Cabaletta Bio Inc (CABA) Quote

CABA, under $3

CABA..............................https://stockcharts.com/h-sc/ui?s=CABA&p=W&b=5&g=0&id=p86431144783

Congrats!  

I'm out at $4.47. 

Time for another pullback to get back in.

Took rest off $4.40s

Let go some more $3.78 

Nice hit $3.55 ditching half here ride the rest into profit land $3.55-$6.11

Been a beauty bottom feeder past week approaching $3 next zone is broad $3.55- $6.11 by end of year looks good

This one looks like it will go to a dollar short term. "LN patient with Grade 4 ICANS likely related to infection, so protocol amended to delay infusion by at least 2 weeks in patient with fever at BL." This statement proposes an immediate threat to favorable results. MHO

I'm loving CABA at this $3.00 level. Does anyone know the next catalyst and the timeframe?

CABA under $5

CABA new 52 week low

CABA under $8

CABA under $10

CABA 10Q due 3/22

CABA new 52 week high

Great call!

Nice call here.
Looking back at chart.
Beautiful cup and handle in October.
Wow.

Sold last week .85 to 8.75-$9.00 in less than 4 months.

$CABA

And now?

https://twitter.com/Okame5208/status/1582912029345529856

https://finance.yahoo.com/quote/CABA?p=CABA

https://www.cabalettabio.com/

Awesome

Cabaletta Bio Announces CABA-201, a Newly Designed CD19-Targeting CAR T Cell Therapy Engineered to Address a Broad Range of Autoimmune Diseases
October 11 2022 - 07:00AM
GlobeNewswire Inc.
Alert
Print
Share On Facebook

Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies for patients with autoimmune diseases, today announced CABA-201, a newly designed, fully human CD19 chimeric antigen receptor (CAR) containing a 4-1BB co-stimulatory domain. Cabaletta has obtained an exclusive, worldwide license for the CD19 binder in CABA-201. The CD19 binder is integrated into a dual targeting CAR T therapy that has been evaluated in approximately 20 cancer patients to date in an investigator-initiated trial. We believe the tolerability data generated in these patients support clinical development in patients with autoimmune diseases. In addition, Cabaletta has established an exclusive translational research partnership with Dr. Georg Schett, a pioneer and global leader in the application of CD19-targeting cell therapies in autoimmunity. The collaboration is focused on generation of additional translational data to gain deeper understanding of the immunologic mechanisms of response and clinical insights from ongoing and continued clinical studies in multiple autoimmune disease indications. The construct utilized in these studies has a similar design to CABA-201, sharing the 4-1BB costimulatory domain and the binding region on the CD19 antigen with a fully human binder. With the addition of CABA-201 to its cell therapy pipeline, Cabaletta can potentially address a broad range of autoimmune diseases in indications such as SLE, rheumatoid arthritis, myositis and systemic sclerosis, among others where B cells contribute to disease pathogenesis.

“On the heels of the seminal publication in Nature Medicine last month reporting initial clinical activity and tolerability data from a 4-1BB-containing CD19-CAR T in patients with SLE who experienced durable drug-free clinical and serologic remission with the one-time therapy, we are excited to announce our new pipeline candidate, CABA-201. We believe CABA-201 is favorably designed for patients with autoimmune diseases given its fully human CD19 binder and 4-1BB co-stimulatory domain. Our exclusive translational research partnership with Professor Schett, which is designed to leverage the deep experience and expertise of Cabaletta scientists in autoimmune cell therapy, has the potential to provide us with important and timely insights into patients enrolled in his breakthrough clinical studies,” said Steven Nichtberger, M.D., Chief Executive Officer and Co-founder of Cabaletta. “We have a sufficient cash runway that will allow us to advance CABA-201 in parallel with the DesCAARTes™ and MusCAARTes™ trials employing our chimeric autoantibody receptor (CAAR) technology, with the potential to generate important clinical data readouts for each program. Accelerated by our team’s proven experience in developing cell therapies for patients with autoimmune diseases in logistically complex trials, our next anticipated milestones for CABA-201 are an IND submission in the first half of 2023, and pending FDA clearance of the IND, initial clinical data by the first half of 2024. We believe CABA-201 has the potential to transform treatment of several common autoimmune diseases by providing clinical and serologic remission and a potential to reset the immune system, furthering our mission to develop therapies that deliver deep, durable, and potentially curative responses for patients with autoimmune diseases.”

Data published by Professor Schett and his colleagues in Nature Medicine on September 15, 2022, demonstrate that a CD19-CAR T cell therapy with a 4-1BB co-stimulatory domain following lymphodepletion with fludarabine and cyclophosphamide induced persistent and deep clinical responses in five out of five patients with severe, refractory SLE, with up to 17 months of follow up. The safety profile demonstrated only mild cytokine release syndrome (CRS), with grade 1 CRS observed in three out of five patients, and no neurotoxicity (immune effector cell-associated neurotoxicity syndrome, or ICANS) of any grade observed. New B cells repopulated within five months of CD19-CAR T infusion in all patients, with no evidence of disease recurrence or autoantibodies following repopulation.

“There is significant unmet need in SLE and other autoimmune diseases, where we believe there is strong potential for CD19-targeting cell therapies to provide meaningful responses for patients. The team at Cabaletta has deep expertise in translational research relating to cell therapy in autoimmune patients, which will be complementary to my team’s efforts. Together, through our exclusive translational research partnership, we can more efficiently address questions critical to advancing CD19-targeting cell therapy strategies for patients,” stated Georg Schett, M.D., Professor and Head of the Department of Internal Medicine 3, and Vice President of Research, Friedrich-Alexander University, Erlangen-Nu¨rnberg, Erlangen, Germany.

CABA-201 includes a fully human CD19 binder that was exclusively in-licensed from Nanjing IASO Biotherapeutics, Co., Ltd. (IASO Bio), which currently utilizes the binder in its CT120 product candidate, a 4-1BB-containing tandem CD19xCD22-CAR T cell therapy that has been evaluated in approximately 20 patients with promising tolerability data in an investigator-initiated trial. CT120 is currently in a Phase I clinical trial in China for non-Hodgkin’s Lymphoma.

Transaction Terms with IASO Bio
Under the terms of the agreement, Cabaletta will receive an exclusive, worldwide license to IASO Bio’s CD19 binder for use in autoimmune and alloimmune indications in humans. IASO Bio is eligible to receive up to $162 million in aggregate payments, including an upfront payment and payment upon the achievement of specified development and commercial milestones, along with tiered mid-single digit royalties on future net sales for products that may result from this collaboration agreement.

About Cabaletta Bio
Cabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide a deep and durable, perhaps curative, treatment for patients with autoimmune diseases. The CABA™ platform – encompassing chimeric antigen receptor T cells for autoimmunity (CARTA: CABA-201, a 4-1BB-containing CD19-CAR T) and Cabaletta Bio’s proprietary chimeric autoantibody receptor T cells (CAART: multiple candidates including DSG3-CAART for mucosal pemphigus vulgaris, MuSK-CAART for MuSK myasthenia gravis) – provides multiple opportunities to treat broad and challenging autoimmune diseases. Cabaletta Bio’s headquarters are located in Philadelphia, PA. For more information, visit www.cabalettabio.com and follow us on LinkedIn and Twitter.

Rumors?

https://finance.yahoo.com/news/iaso-biotherapeutics-cabaletta-bio-ink-140632788.html

Rumors:: watch this one fly if true.

Well that proved to be a huge mistake. 40+% LOSS in two weeks.

Oh wow that was luck I guess

Just got 1,67… hope no offering lol

of course $DATS is doing a similar move today

LOL

Message in reply to:
HOW CAN THIS MOVE LIKE ... this on such crazy low volume?

why havent the algos been triggered to flood in with volume?

I dont remember seeing anything like this, is a very long time

HOW CAN THIS MOVE LIKE ... this on such crazy low volume?

why havent the algos been triggered to flood in with volume?

I dont remember seeing anything like this, is a very long time

Contact company!

WHEN ARE CLINICAL NEW DATA available here? i hope soon ! dude with $CABA

In a report released yesterday, Vamil Divan from Mizuho Securities reiterated a Buy rating on Cabaletta Bio (CABA – Research Report), with a price target of $20.00. The company's shares closed last Thursday at $1.71, close to its 52-week low of $1.66. According to TipRanks.com, Divan is a 1-star analyst with an average return of -1.8% and a 48.4% success rate. Divan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Satsuma Pharmaceuticals, and ACADIA Pharmaceuticals. Cabaletta Bio has an analyst consensus of Moderate Buy, with a price target consensus of $20.00. See Insiders’ Hot Stocks on TipRanks >> Cabaletta Bio's market cap is currently $48.
https://www.tipranks.com/news/blurbs/mizuho-securities-thinks-cabaletta-bios-stock-is-going-to-recover-2?utm_source=advfn.com&utm_medium=referral

Cabaletta Bio Inc. is a clinical-stage biotechnology company. The Company is focused on discovery and development of engineered T-cell therapies for B cell-mediated autoimmune diseases. The T cells are designed to selectively bind and eliminate B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. The Company's lead CAAR T cell product candidate is designed based on chimeric antigen receptor (CAR), and its T cell technology has been developed and is marketed for the treatment of B cell cancers. The Company has discovered and developed four product candidates, including its lead product candidate, to potentially treat patients with mucosal pemphigus vulgaris (mPV), and three additional product candidates that have demonstrated specific and selective target engagement in vitro. Its product pipelines include DSG3-CAART, DSG3/1-CAART, Musk-CAART and FVIII-CAART.